A Retrospective Study of First-Line Therapy Involving Immune Checkpoint Inhibitors in Patients With Poor Risk Metastatic Renal Cell Carcinoma

A Retrospective Study of First-Line Therapy Involving Immune Checkpoint Inhibitors in Patients With Poor Risk Metastatic Renal Cell Carcinoma

PurposePatients with International Metastatic RCC Database Consortium (IMDC) poor risk metastatic renal cell carcinoma (mRCC) rarely respond to first-line tyrosine kinase inhibitors (TKIs) including sunitinib, and carries a very poor prognosis. In recent years, combination therapy involving immune c...

Full description

Bibliographic Details
Main Authors: Hyunji Jo, Joohyun Hong, Hongsik Kim, Hye Ryeon Kim, Ghee Young Kwon, Kyung A. Kang, Sung Yoon Park, Chan Kyo Kim, Byung Kwan Park, Jae Hoon Chung, Wan Song, Minyong Kang, Hyun Hwan Sung, Hwang Gyun Jeon, Byong Chang Jeong, Seong Il Seo, Seong Soo Jeon, Hyun Moo Lee, Se Hoon Park
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-04-01
Series:Frontiers in Oncology
Subjects:
immunotherapy
immune checkpoint inhibitors
renal cell carcinoma
IMDC poor-risk
overall survival
sunitinib
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.874385/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.874385/full

Similar Items